{"id":"immune-checkpoint-inhibitors-or-docetaxel","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Immune-related adverse events (pneumonitis, colitis, hepatitis)"},{"rate":null,"effect":"Peripheral neuropathy"}]},"_chembl":{"chemblId":"CHEMBL92","moleculeType":"Small molecule","molecularWeight":"807.89"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Immune checkpoint inhibitors (such as PD-1/PD-L1 inhibitors) block inhibitory signals that allow tumors to evade the immune system, thereby activating T-cell mediated anti-tumor responses. Docetaxel is a taxane chemotherapy agent that stabilizes microtubules and induces apoptosis in rapidly dividing cancer cells. The combination may provide synergistic benefit by combining direct cytotoxic effects with immune activation.","oneSentence":"This is a combination approach using immune checkpoint inhibitors to enhance anti-tumor immunity and/or docetaxel chemotherapy to directly kill cancer cells.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:15:37.569Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer (Phase 3 trials)"}]},"trialDetails":[{"nctId":"NCT06745908","phase":"PHASE3","title":"ResQ201A: Clinical Trial Of N-803 Plus TISLELIZUMAB And DOCETAXEL Versus DOCETAXEL Monotherapy In Participants With Advanced Or Metastatic Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2025-10-01","conditions":"NSCLC Stage IV","enrollment":460},{"nctId":"NCT02973789","phase":"PHASE3","title":"Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)","status":"COMPLETED","sponsor":"NovoCure GmbH","startDate":"2016-12","conditions":"Nonsmall Cell Lung Cancer, NSCLC","enrollment":291},{"nctId":"NCT06989112","phase":"PHASE3","title":"DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-03-27","conditions":"Endometrial Cancer","enrollment":600},{"nctId":"NCT07069712","phase":"PHASE2","title":"A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-07-17","conditions":"Gastroesophageal Adenocarcinoma","enrollment":100},{"nctId":"NCT06951646","phase":"PHASE2","title":"ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)","status":"RECRUITING","sponsor":"Second Xiangya Hospital of Central South University","startDate":"2026-03-10","conditions":"Non Small Cell Lung Cancer, Immune Checkpoint Inhibitors (ICIs)","enrollment":70},{"nctId":"NCT06545955","phase":"PHASE3","title":"A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer","status":"RECRUITING","sponsor":"Ferring Pharmaceuticals","startDate":"2024-10-01","conditions":"Non-muscle Invasive Bladder Cancer With Carcinoma in Situ","enrollment":250},{"nctId":"NCT06632327","phase":"PHASE3","title":"Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2024-12-11","conditions":"Resectable Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8","enrollment":1100},{"nctId":"NCT06937905","phase":"PHASE3","title":"Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs)","status":"RECRUITING","sponsor":"Intergroupe Francophone de Cancerologie Thoracique","startDate":"2026-02-06","conditions":"Neuroendocrine Carcinoma","enrollment":129},{"nctId":"NCT06340568","phase":"PHASE3","title":"A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2025-06-10","conditions":"Endometrial Cancer","enrollment":480},{"nctId":"NCT07354984","phase":"PHASE2","title":"A Single-Arm Phase II Clinical Study of Docetaxel Combined With Nimotuzumab and Pucotenlimab as Second-Line and Beyond Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-01-01","conditions":"Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma","enrollment":30},{"nctId":"NCT03228667","phase":"PHASE2","title":"QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors","status":"ACTIVE_NOT_RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2018-12-11","conditions":"Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Urothelial Carcinoma","enrollment":40},{"nctId":"NCT07317778","phase":"PHASE2","title":"Chemotherapy With or Without Adebrelimab and T-DXh as Neoadjuvant Therapy for HR+/HER2 Low Early Stage Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2026-02-15","conditions":"Breast Cancer Early Stage Breast Cancer (Stage 1-3), HR Positive/HER2 Low Breast Cancer","enrollment":249},{"nctId":"NCT06699212","phase":"PHASE3","title":"A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases","status":"RECRUITING","sponsor":"Rakuten Medical, Inc.","startDate":"2024-12-24","conditions":"Recurrent Head and Neck Squamous Cell Carcinoma","enrollment":412},{"nctId":"NCT06463665","phase":"PHASE2","title":"Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer","status":"RECRUITING","sponsor":"Genelux Corporation","startDate":"2024-09-26","conditions":"Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma, Metastatic Non-squamous Non Small Cell Lung Cancer","enrollment":142},{"nctId":"NCT07134413","phase":"PHASE2","title":"QL1706/Bevacizumab ± Chemotherapy in Post-ICI Non-Squamous NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Guangdong Association of Clinical Trials","startDate":"2025-08","conditions":"NSCLC","enrollment":77},{"nctId":"NCT03170960","phase":"PHASE1","title":"Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Exelixis","startDate":"2017-09-05","conditions":"Urothelial Carcinoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer","enrollment":914},{"nctId":"NCT04062708","phase":"PHASE2","title":"CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance Foundation Trials, LLC.","startDate":"2021-03-10","conditions":"Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer","enrollment":38},{"nctId":"NCT05431270","phase":"PHASE1, PHASE2","title":"Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 MAb, Administered Alone and in Combination with a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)","status":"RECRUITING","sponsor":"Phanes Therapeutics","startDate":"2022-08-11","conditions":"Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma","enrollment":40},{"nctId":"NCT06137378","phase":"PHASE2","title":"European Larynx Organ Preservation Study (ELOS) [MK-3475-C44]","status":"RECRUITING","sponsor":"University of Leipzig","startDate":"2024-04-17","conditions":"Squamous Cell Carcinoma of Head and Neck, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma Stage III","enrollment":140},{"nctId":"NCT05583188","phase":"PHASE4","title":"Neoadjuvant Aliya™ PEF Soft Tissue Ablation With Systemic Therapy in Early-Stage Resectable NSCLC","status":"TERMINATED","sponsor":"Galvanize Therapeutics, Inc.","startDate":"2023-02-01","conditions":"NSCLC","enrollment":5},{"nctId":"NCT02654587","phase":"PHASE3","title":"OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor Failure","status":"TERMINATED","sponsor":"OSE Immunotherapeutics","startDate":"2016-02-12","conditions":"Non Small Cell Lung Cancer","enrollment":219},{"nctId":"NCT06208033","phase":"EARLY_PHASE1","title":"SMET12 and Toripalimab Combined Chemotherapy in Patients With EGFR Positive Advanced Non-small Cell Lung Cancer (NSCLC)","status":"UNKNOWN","sponsor":"Fujian Cancer Hospital","startDate":"2024-01-10","conditions":"EGFR Positive Non-small Cell Lung Cancer","enrollment":40},{"nctId":"NCT04146064","phase":"","title":"Breathomics as Predictive Biomarker for Checkpoint Inhibitor Response","status":"UNKNOWN","sponsor":"University Health Network, Toronto","startDate":"2020-02-24","conditions":"NSCLC, Melanoma, Kidney Cancer","enrollment":425},{"nctId":"NCT05834413","phase":"NA","title":"Clinical Study on the Prevention of Driver Gene Negative II-IIIa Lung Cancer Recurrence and Metastasis by Staged Chinese Herbal Medicine Combined With Chemotherapy and Immune Checkpoint Inhibitors","status":"NOT_YET_RECRUITING","sponsor":"Shanghai University of Traditional Chinese Medicine","startDate":"2023-05-01","conditions":"Lung Cancer","enrollment":367},{"nctId":"NCT05649163","phase":"","title":"Real-world Study of HER2-overexpressed Advanced Solid Tumors After Progression of First-line Standard Therapy","status":"UNKNOWN","sponsor":"Shen Lin","startDate":"2023-01","conditions":"HER2, Advanced Gastric Cancer, Advanced Gastroesophageal Junction Adenocarcinoma","enrollment":306},{"nctId":"NCT05552807","phase":"PHASE1","title":"SCT200 in Combination With SCT-I10A/Paclitaxel/Docetaxel in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma","status":"UNKNOWN","sponsor":"Sinocelltech Ltd.","startDate":"2022-06-15","conditions":"Head and Neck Squamous Carcinoma","enrollment":120},{"nctId":"NCT04115410","phase":"","title":"PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study","status":"UNKNOWN","sponsor":"Sungkyunkwan University","startDate":"2020-07-01","conditions":"Carcinoma, Non-Small-Cell Lung, Immune-Related Adverse Events","enrollment":4724}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":82976,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Immune checkpoint inhibitors or docetaxel","genericName":"Immune checkpoint inhibitors or docetaxel","companyName":"NovoCure GmbH","companyId":"novocure-gmbh","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a combination approach using immune checkpoint inhibitors to enhance anti-tumor immunity and/or docetaxel chemotherapy to directly kill cancer cells. Used for Non-small cell lung cancer (Phase 3 trials).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}